Literature DB >> 10196039

Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation.

H U Meier-Kriesche1, K W Finkel, J J Gitomer, T D DuBose.   

Abstract

Citrate is known to induce acute hypocalcemia in patients undergoing liver transplantation during the anhepatic phase. We describe the case of a 71-year-old woman with fulminant hepatic failure secondary to hepatitis A, who was started on continuous venovenous hemodialysis (CVVHD) for acute renal failure. Because anticoagulation with heparin was untenable, regional anticoagulation was accomplished by trisodium citrate (46.7%) infusion. Unfortunately, severe hypocalcemia developed when citrate accumulated because of impaired hepatic metabolism. Because of chelation by citrate, the ionized calcium concentration declined to values as low as 2.72 mg/dL (normal, 4.5 to 5.6 mg/dL), whereas the total calcium concentration remained in the normal range. With an unusually high calcium chloride infusion rate via a central line (up to 140 mL/h of 10 mEq/dL CaCl2) and additional boli of CaCl2 (for a total of 190 mEq), the ionized calcium concentration could be maintained at target levels. Nevertheless, the ionized calcium concentration was maintained in the normal range, and the total calcium concentration increased to a value as high as 15 mg/dL. Thus, the total to ionized calcium ratio was 3.5:1. After 24 hours of treatment, trisodium citrate infusion was gradually reduced from 15 mL/h to 7 mL/h, and the calcium chloride infusion was decreased to 50 mL/h. Nevertheless, persistence of the elevated total to ionized calcium ratio (3:1) indicated citrate accumulation likely secondary to decreased hepatic metabolism. Using this approach, the patient was successfully maintained on CVVHD with regional citrate anticoagulation for a total of 11 days without any additional complications. We conclude that CVVHD with regional citrate anticoagulation can be used in patients with acute hepatic failure if increased CaCl2 requirements are anticipated and if citrate is infused at a lower rate compatible with decreased citrate metabolism. Citrate accumulation should be suspected in patients with an elevated total to ionized Ca++ ratio during CVVHD with citrate anticoagulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10196039     DOI: 10.1016/s0272-6386(99)70249-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

Review 1.  Regional citrate anticoagulation for RRTs in critically ill patients with AKI.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Enrico Fiaccadori
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

2.  Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis.

Authors:  John A Clark; Gerald Schulman; Thomas A Golper
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 8.237

3.  Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy.

Authors:  Josée Bouchard; François Madore
Journal:  NDT Plus       Date:  2008-12-09

4.  Coupled Plasma Filtration and Adsorption (CPFA): A Single Center Experience.

Authors:  Rizna Abdul Cader; Halim Abdul Gafor; Rozita Mohd; Wei Yen Kong; Norazimah Arshad; Norella Kong
Journal:  Nephrourol Mon       Date:  2013-09-15

5.  Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction.

Authors:  Matthias Klingele; Theresa Stadler; Danilo Fliser; Timo Speer; Heinrich V Groesdonk; Alexander Raddatz
Journal:  Crit Care       Date:  2017-11-29       Impact factor: 9.097

6.  Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study.

Authors:  Shaikh A Nurmohamed; Borefore P Jallah; Marc G Vervloet; Gul Yldirim; Pieter M ter Wee; A B Johan Groeneveld
Journal:  BMC Nephrol       Date:  2013-04-18       Impact factor: 2.388

7.  Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study.

Authors:  Caroline Schultheiß; Bernd Saugel; Veit Phillip; Philipp Thies; Sebastian Noe; Ulrich Mayr; Bernhard Haller; Henrik Einwächter; Roland M Schmid; Wolfgang Huber
Journal:  Crit Care       Date:  2012-08-22       Impact factor: 9.097

8.  Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study.

Authors:  Harin Rhee; Brendan Berenger; Ravindra L Mehta; Etienne Macedo
Journal:  Am J Kidney Dis       Date:  2021-03-30       Impact factor: 11.072

9.  Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation.

Authors:  Justyna Kozik-Jaromin; Volker Nier; Uwe Heemann; Bernhard Kreymann; Joachim Böhler
Journal:  Nephrol Dial Transplant       Date:  2009-02-05       Impact factor: 5.992

10.  Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.

Authors:  Yong Kyu Lee; Hae Won Lee; Kyu Hun Choi; Beom Seok Kim
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.